NFKB1 and neoplasm: Nonetheless, EP treatment significantly inhibits the recognition of these two proteins, augments the death of tumor cells, inhibits the NF-κB/STAT3 pathway, and hinders the instigation of inflammatory response (Liu et al., 2019a).